MVM Partners

MVM Partners is a London-based private equity and venture capital firm with an office in Boston. Founded in 1997, it focuses on healthcare and life sciences, investing in biotechnology, medical devices, diagnostics, gene therapy, digital health and related areas, as well as healthcare services and research tools. The firm supports start-up through growth-stage companies, targeting differentiated technology with patent protection and large addressable markets that address unmet medical needs. Investment sizes typically range from five million to thirty million pounds per portfolio company, with aggregate commitments in the tens of millions over the life of a holding. It may invest across equity and debt instruments and often seeks a seat on the board of portfolio companies to guide development. MVM Partners operates multiple funds and pursues opportunities globally, including Western Europe and the Eastern United States.

Eric Bednarski Ph.D

Partner

Thomas Casdagli

Partner

Eric Fritz Ph.D

Partner

Hugo Harrod

Partner

Talia Kirschbaum

Partner

Past deals in Hospital

VitalConnect

Venture Round in 2025
VitalConnect is a company that specializes in wearable biosensor technology for wireless patient monitoring. It develops innovative solutions that enable continuous monitoring and recording of patients' vital signs through an adhesive patch applied to the body. The technology integrates expertise in biomedical engineering, data analytics, and chip design, allowing vital data to be displayed on mobile devices and computer systems. This capability empowers healthcare professionals to respond promptly to urgent situations and gain valuable insights into patient health, facilitating informed decision-making in both inpatient and outpatient settings, including hospital monitoring, post-discharge care, and cardiac monitoring.

VERO Biotech

Series E in 2021
VERO Biotech LLC is a biopharmaceutical company focused on developing and commercializing innovative products for patients with pulmonary and cardiac conditions. The company specializes in inhaled nitric oxide (NO) delivery systems, which are designed for both hospital settings and longer-term home use. Utilizing its proprietary GeNOsyl drug delivery technology, VERO Biotech offers a user-friendly solution that includes a single-use drug cassette coupled with a portable console or wearable controller. This technology aims to provide a safe and consistent administration of nitric oxide for various therapeutic applications, addressing unmet medical needs such as pulmonary arterial hypertension and hypoxic respiratory failure in newborns. Founded in 2006 and based in Atlanta, Georgia, VERO Biotech was previously known as GeNO LLC.

VitalConnect

Series C in 2017
VitalConnect is a company that specializes in wearable biosensor technology for wireless patient monitoring. It develops innovative solutions that enable continuous monitoring and recording of patients' vital signs through an adhesive patch applied to the body. The technology integrates expertise in biomedical engineering, data analytics, and chip design, allowing vital data to be displayed on mobile devices and computer systems. This capability empowers healthcare professionals to respond promptly to urgent situations and gain valuable insights into patient health, facilitating informed decision-making in both inpatient and outpatient settings, including hospital monitoring, post-discharge care, and cardiac monitoring.

Cheetah Medical

Series C in 2017
Cheetah Medical, Inc. is a medical technology company specializing in non-invasive solutions for monitoring cardiac output and hemodynamic parameters in critically ill patients. Its flagship product, the NICOM Noninvasive Cardiac Output and Hemodynamic Monitoring System, is designed for clinical applications such as fluid optimization, hemodynamic differential diagnosis, and drug titration. This system provides vital information for conditions like hypovolemic, septic, and cardiogenic shock, as well as aiding in the management of shortness of breath and acute renal failure. The NICOM system is FDA cleared and CE marked, recognized for its substantial equivalence to traditional monitoring systems. Cheetah Medical distributes its products to medical centers across various countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, the company also has offices in Vancouver, Washington, and Tel Aviv, Israel. Cheetah Medical is committed to research and development, partnering closely with clinicians to enhance patient outcomes and improve healthcare efficiency.

Cheetah Medical

Series C in 2014
Cheetah Medical, Inc. is a medical technology company specializing in non-invasive solutions for monitoring cardiac output and hemodynamic parameters in critically ill patients. Its flagship product, the NICOM Noninvasive Cardiac Output and Hemodynamic Monitoring System, is designed for clinical applications such as fluid optimization, hemodynamic differential diagnosis, and drug titration. This system provides vital information for conditions like hypovolemic, septic, and cardiogenic shock, as well as aiding in the management of shortness of breath and acute renal failure. The NICOM system is FDA cleared and CE marked, recognized for its substantial equivalence to traditional monitoring systems. Cheetah Medical distributes its products to medical centers across various countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, the company also has offices in Vancouver, Washington, and Tel Aviv, Israel. Cheetah Medical is committed to research and development, partnering closely with clinicians to enhance patient outcomes and improve healthcare efficiency.

Cheetah Medical

Venture Round in 2013
Cheetah Medical, Inc. is a medical technology company specializing in non-invasive solutions for monitoring cardiac output and hemodynamic parameters in critically ill patients. Its flagship product, the NICOM Noninvasive Cardiac Output and Hemodynamic Monitoring System, is designed for clinical applications such as fluid optimization, hemodynamic differential diagnosis, and drug titration. This system provides vital information for conditions like hypovolemic, septic, and cardiogenic shock, as well as aiding in the management of shortness of breath and acute renal failure. The NICOM system is FDA cleared and CE marked, recognized for its substantial equivalence to traditional monitoring systems. Cheetah Medical distributes its products to medical centers across various countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, the company also has offices in Vancouver, Washington, and Tel Aviv, Israel. Cheetah Medical is committed to research and development, partnering closely with clinicians to enhance patient outcomes and improve healthcare efficiency.

eZono

Venture Round in 2013
eZono AG is a company based in Jena, Germany, specializing in the design, development, and marketing of tablet ultrasound systems. Founded in 2004, eZono offers a range of products, including the eZono 4000, a system suited for use in operating rooms and critical care areas, and the eZono 3000, a portable ultrasound solution for point-of-care imaging. The company also provides eZGuide, a needle guidance technology that enhances visualization of needle placement, alongside educational Cue Cards that serve as reference materials for various clinical procedures. eZono's products are utilized across multiple medical fields, such as anesthesiology, pain management, emergency medicine, and simulation centers. By empowering non-traditional ultrasound users, eZono aims to improve clinical outcomes, enhance patient satisfaction, and reduce costs associated with ultrasound technology.

Patient Connect

Series A in 2011
Patient Connect is a pioneering company that specializes in delivering evidence-based clinical messages directly at the point of care. The company operates a clinical information platform designed to enhance patient support and education. By providing clinically-driven communications, Patient Connect aims to help patients understand the importance of their medications, ensure proper usage, and address potential side effects and compliance issues. With a strong presence in the healthcare sector, the company has successfully completed over 40 customer projects for a significant number of leading pharmaceutical companies in the UK, establishing itself as a key player in the integration of clinical messaging services within retail and hospital pharmacies.

Cheetah Medical

Series B in 2010
Cheetah Medical, Inc. is a medical technology company specializing in non-invasive solutions for monitoring cardiac output and hemodynamic parameters in critically ill patients. Its flagship product, the NICOM Noninvasive Cardiac Output and Hemodynamic Monitoring System, is designed for clinical applications such as fluid optimization, hemodynamic differential diagnosis, and drug titration. This system provides vital information for conditions like hypovolemic, septic, and cardiogenic shock, as well as aiding in the management of shortness of breath and acute renal failure. The NICOM system is FDA cleared and CE marked, recognized for its substantial equivalence to traditional monitoring systems. Cheetah Medical distributes its products to medical centers across various countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, the company also has offices in Vancouver, Washington, and Tel Aviv, Israel. Cheetah Medical is committed to research and development, partnering closely with clinicians to enhance patient outcomes and improve healthcare efficiency.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.